| http://www.w3.org/ns/prov#value | - The growing market for targeted mutation treatmentsSince Roche is footprint in NSCLC treatments is so large, other companies, such as Pfizer and Clovis Oncology, have tried to carve out new niche markets with treatments targeting specific mutations of NSCLC instead.
|
